Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
11:06am, Friday, 20'th Jun 2025
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.
I'm Buying Dividend Giants At Huge Discounts
09:00am, Friday, 20'th Jun 2025
Now is a great time to be an income and value investor, particularly in the energy and pharmaceutical spaces. I highlight 2 undervalued names that provide well-covered dividends with a strong growth o
Bristol Myers Squibb Announces Dividend
04:16pm, Tuesday, 17'th Jun 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note
06:46pm, Monday, 16'th Jun 2025
Bristol Myers Squibb (BMY) concluded the recent trading session at $48.66, signifying a -2.19% move from its prior day's close.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #18ICML--BMS Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi.
2 Beaten-Down Dividend Stocks to Buy Right Now
04:25am, Monday, 16'th Jun 2025
Stocks experienced significant volatility this year, which can sometimes make it challenging to keep a positive outlook. In times like these, it's worthwhile to remember that stock-market swings, even
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?
10:50am, Friday, 13'th Jun 2025
BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.
BMY Reports Positive Data on Sotyktu From Arthritis Study
10:16am, Thursday, 12'th Jun 2025
Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.
Dividend Harvesting Portfolio Week 223: $22,300 Allocated, $2,310.77 In Projected Dividends
09:00am, Thursday, 12'th Jun 2025
The Dividend Harvesting Portfolio hit a new all-time high, delivering a 26.95% return and $2,310.77 in forward annual dividend income. I continue to diversify across ETFs, REITs, CEFs, BDCs, and equit
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
06:45am, Thursday, 12'th Jun 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025.
Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
01:43pm, Wednesday, 11'th Jun 2025
Bristol-Myers Squibb Company (NYSE:BMY ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 10:00 AM ET Company Participants Adam Lenkowsky - Executive VP & Chief Commercialization O
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
10:01am, Wednesday, 11'th Jun 2025
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EULAR--BMS Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu.
Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFI
